Cefadol

Quick links to important sections

Cefadol

Method of action: Bactericidal

Treatment option: Meningitis, Sepsis, Endocarditis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefadol

Property Description
Active ingredient Cefamandole (supplied as Cefamandole nafate)
Form Sterile Powder for Injection
Pharmacological class beta-Lactam Antibiotic (Second-Generation Cephalosporin)
Common use Treatment of serious bacterial infections
Origin Semisynthetic

Cefadol is a prescription-only medication designed to eliminate bacteria causing systemic infections. Its active component, cefamandole, belongs to the second-generation cephalosporin family of beta-lactam antibiotics. The drug is of semisynthetic origin and possesses a relatively broad-spectrum capability against a range of Gram-positive and Gram-negative bacterial pathogens. The primary medical purpose of Cefadol is to control and resolve these severe bacterial processes throughout the body, particularly when treating infections that require an aggressive, injectable antibiotic.


Cefadol's Composition and Delivery Form

The therapeutic component is cefamandole, which is primarily supplied in its inactive precursor form, cefamandole nafate. This compound is classified as a prodrug. The use of a prodrug formulation is clinically recognized for optimizing the drug's stability prior to administration. As a single-ingredient product, Cefadol is prepared as a dry, sterile powder for injection that must be reconstituted with a diluent prior to use. This preparation is strictly intended for parenteral administration via either intramuscular or intravenous injection, a key feature that differentiates it from orally administered antibiotics.


How Does Cefadol Affect Bacteria?

Cefadol affects bacteria through bactericidal activity, which means the medication is designed to directly kill the invading infectious organisms rather than merely slowing their growth. The medication achieves this by disrupting the bacteria's ability to build and maintain their protective outer structure, known as cell-wall synthesis. It possesses a high level of activity against various bacteria often implicated in respiratory, skin, and urinary tract infections. Cefadol is an effective option for rapidly clearing these bacterial pathogens, leading to the resolution of the underlying infection.

Regulatory References

  1. PubChem Compound: Cefamandole Nafate

What side effects are possible with Cefadol?

Possible side effects and safety information

The official safety profile for Cefadol (Cefamandole nafate) documents adverse reactions primarily classified by the physiological systems they affect, emphasizing high-level consequences and specific contextual limitations.

Adverse reactions are grouped into key system-organ classes, including Immune System Disorders, Skin and Subcutaneous Tissue Disorders, Blood and Lymphatic System Disorders, and Gastrointestinal Disorders. The label notes that hypersensitivity reactions, such as maculopapular rash, urticaria, and eosinophilia, are documented.

Key Regulatory Safety Classifications

Category Officially Documented Information
Serious Reactions Anaphylaxis (a severe systemic allergic reaction) and pseudomembranous colitis are explicitly listed in regulatory documents.
Frequency Thrombocytopenia (low platelet count) is reported as occurring rarely.
Safety Patterns Neutropenia (low white blood cell count) has been associated with long courses of treatment.
Specific Risks Symptoms including nausea, vomiting, and hypotension may follow the ingestion of alcohol during use.

Population and Contextual Safety Notes

The product labeling notes that individuals with a history of allergy, particularly to penicillin, may be more likely to experience hypersensitivity reactions. Furthermore, the safety of Cefadol has not been established in infants under one month of age. For patients with renal impairment, the regulatory documentation specifies that a modification of the dosage regimen is required, alongside recommended serum concentration monitoring. Cross-allergenicity with penicillins is documented, and there is a noted risk of nephrotoxicity when administered with aminoglycoside antibiotics.

Overdose and Emergency Response

Overdose and When to Seek Help

Note: This product name is associated with the active ingredient acetaminophen (paracetamol). All overdose information is based on official government regulatory warnings for acetaminophen overdose.

Overdose Presentation Key Clinical Manifestations
Hepatic Toxicity (Liver Damage) Nausea, vomiting, loss of appetite, stomach pain (which may be in the right upper quadrant of the abdomen), and jaundice (yellowing of the skin or eyes).
Severity Severe liver damage can lead to acute liver failure, which may require a liver transplant or result in death. Symptoms may be delayed for 24 hours or longer after ingestion.

Circumstances Associated with Overdose Risk

Overdose is generally defined by an intake exceeding the maximum recommended total daily dose of acetaminophen from all sources. For adults, the maximum dose is 4,000 milligrams (4 grams) in a 24-hour period. Risk is heightened when taking this medication alongside other products (both prescription and over-the-counter) that also contain acetaminophen.

When Immediate Medical Attention is Required

Seek immediate medical help or contact a poison control center if you suspect an overdose has occurred, even if you do not yet feel symptoms. Initial symptoms can be minor or flu-like, and may not reflect the severity of internal organ damage. Individuals with a history of liver disease or those who consume three or more alcoholic drinks daily are at a higher risk of severe liver injury from this medication.

Therapeutic Uses of Cefadol

What Cefadol Treats: Main Uses and Benefits

Cefadol (Cefamandole nafate) is commonly used to address conditions involving serious bacterial infections across several key organ systems and is relevant for prophylactic support in surgery. These therapeutic applications are generally associated with infections of the lower respiratory tract, genito-urinary tract, bones and joints, bloodstream, skin and soft tissue, and for surgical prophylaxis.


The medication is applied in acute symptomatic episodes affecting systems where symptoms create noticeable functional strain and discomfort, such as difficulty breathing or persistent fever in pneumonia. In these contexts, Cefadol is used for managing groups of symptoms that may become intense or disruptive. In these contexts, it provides support that helps ease the overall symptom burden associated with these critical conditions.

“This medication is commonly used in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.”

Cefadol is also utilized as a preventative measure around major or contaminated surgical procedures. This use assists with maintaining functional stability during the healing process by supporting infection management related to the surgical site.

Quick Fact: Relief for Systemic Stress
Cefadol is relevant for easing symptoms related to systemic imbalance and heightened physiological activity, particularly the fever and malaise associated with acute or episodic changes.

Regulatory References

  1. Irish Medicines Board (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Cefadol?

This medicine is subject to strict eligibility rules based on regulatory labeling, primarily defined by contraindications and conditions requiring cautious use.

Populations Who Must NOT Use the Medicine

Use is contraindicated (absolutely forbidden) for:

  • Individuals with a known allergy or hypersensitivity to the cephalosporin class of antibiotics (which includes this medicine).
  • Individuals with a known allergy or hypersensitivity to the drug Cefadol itself.

Conditional or Restricted Use

Use is allowed only under specific conditions or with caution for the following populations:

Population/Condition Eligibility Status
Impaired Kidney Function Conditional. Dosage must be adjusted according to the degree of renal impairment to prevent drug accumulation.
History of Penicillin Allergy Use with Caution. A risk of cross-hypersensitivity among beta-lactam antibiotics is documented.
History of Colitis/GI Disease Use with Caution. The medicine may carry a risk of Clostridioides difficile-associated diarrhea (CDAD).
Pregnancy/Lactation Conditional. Use only if clearly needed. The drug is known to be excreted into human milk.
Children Eligible. Usefulness is established, with dosing based on body weight.

What should I know about interactions with other medicines?

Cefadol (Cefamandole nafate) has officially documented interaction profiles established by regulatory authorities that necessitate specific constraints and procedural monitoring. These interactions are categorized based on how they affect Cefadol exposure or influence physiological risks.

Official Interaction Statements

Interacting Product Category Official Constraint or Outcome
Renal Tubular Secretion Inhibitors (e.g., Probenecid) Co-administration leads to reduced clearance and an increase in Cefamandole serum concentration by inhibiting its renal tubular secretion.
Alcohol (Ethanol) The drug’s metabolism creates a risk of a disulfiram-like reaction, requiring mandatory avoidance of all alcohol during treatment and for at least 72 hours after the last dose.
Oral Anticoagulants Co-use is associated with an increased risk of bleeding due to a recognized additive effect on coagulation parameters.
Aminoglycosides or Diuretics Concurrent administration requires careful monitoring of renal function due to a recognized increased potential for nephrotoxicity.
Neuromuscular Blocking Agents Officially documented to increase the activity of these co-administered agents.

Connection to the Overall Interaction Profile

The regulatory profile defines the drug’s interaction structure through mandatory constraints: pharmacokinetic constraints that elevate drug exposure (e.g., with Probenecid) and pharmacodynamic risk enhancement that increases the potential for adverse physiological outcomes (e.g., bleeding risk and nephrotoxicity). This profile includes specific timing-based rules for substance avoidance, directly linking the drug's enzyme-mediated properties to an administration restriction.

Mechanism of Action

How Cefadol Works: Mechanism of Action

Cefadol (Cefamandole) is a bactericidal antibiotic that functions by targeting a process unique to bacterial structure. The mechanism is centered on the irreversible inhibition of bacterial cell wall synthesis.

The drug directly targets Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for constructing the peptidoglycan layer of the cell wall. Cefamandole acts as a suicide substrate, forming a stable, covalent bond with the active site of the PBP transpeptidases to immediately disable them.

By disabling the PBPs, the drug effectively blocks the final cross-linking step in the cell wall synthesis pathway, preventing the structural rigidity needed for bacterial survival. This disruption of integrity results in a profound cellular consequence: the bacterial cell cannot withstand its internal osmotic pressure, leading to the cell's rupture and death (lysis). This highly specific action induces osmotic lysis and the subsequent destruction of the bacterial cells.

Dosage and Administration Information

Administration Method

Cefadol is typically administered orally in the form of tablets. To facilitate absorption and minimize potential gastrointestinal discomfort, it is generally recommended to take the medication after meals. The tablets should be swallowed whole with a sufficient amount of water.

Consistency in Schedule

Maintaining a regular schedule helps ensure a steady concentration of the active ingredient in the bloodstream. It is common practice to space the intake at even intervals throughout the day.

Proper Storage

To maintain the integrity of the medication, it should be stored according to the following guidelines:

  • Keep the medication in its original packaging to protect it from light and moisture.
  • Store at room temperature, avoiding areas of excessive heat or humidity (such as bathrooms).
  • Ensure the storage location is out of reach of children and pets.

Duration of Use

The length of time this medication is used depends on the specific condition being addressed and the individual response to the treatment. Users are generally advised to follow the duration outlined by their healthcare provider, even if symptoms appear to improve early in the process.

Recent Clinical Evidence

Research evidence / Overview of studies for Cefadol

Evidence for Use in Surgical Prophylaxis

Research has explored whether Cefadol could be used to prevent infection after certain types of surgical procedures. These studies, which include Randomized Controlled Trials (RCTs) and analyses that combine multiple trials, focused on adult patients undergoing procedures where the risk of infection is present (classified as clean-contaminated surgery). The main outcomes monitored were measurements of Surgical Site Infection (SSI) rates, including those affecting the skin surface and deeper tissues.

Studies reported measurements describing the patterns observed in the occurrence of SSI when Cefadol was used. The findings describe how SSI rates evolved in the observed populations compared to those receiving a different agent studied in the trials or placebo. Some of the original comparative trials are historical, which means direct, modern comparative evidence is lacking against the most current standard agents now in wide use. Long-term effects are not fully established regarding how the use of this agent during surgery was associated with sustained healing or recurrence rates over many months, as the studies focused on the short-term post-operative period.


Evidence for Use in Treating Lower Respiratory Tract Infections

Cefadol was evaluated in research for its use in conditions characterized by acute or disruptive episodes in the lungs, such as serious pneumonia. These randomized clinical trials typically included hospitalized adult patients. The primary outcomes monitored were outcomes related to systemic or functional imbalance, specifically looking at how symptoms like fever and respiratory distress changed over the study period, alongside the clearance of the specific bacteria found in the respiratory samples.

Research highlights changes measured during the study period, including the observed rates of patient recovery and resolution of acute symptoms. Studies also reported patterns related to the eradication of the infecting bacteria. The overall evidence base varies across studies, as many of the foundational comparative trials are older, meaning the comparisons were often against previous standards of care. Also, the follow-up durations were limited, focusing primarily on the changes seen during the short course of treatment itself.


Evidence for Use in Treating Other Systemic Infections

Research describes Cefadol was studied for its application in several other serious, body-wide infections, including skin and soft tissue infections (SSTI), infections of the bone and joints, and bloodstream infections (septicemia).

For skin and soft tissue infections, studies explored the clinical response in hospitalized adult patients. Findings describe patterns observed in the resolution of visible infection signs. Sample sizes were modest in some of these descriptive reports, and comparative evidence is lacking against other standard treatments for these conditions.

Evidence for bone and joint infections is largely derived from case reports and small descriptive studies that included both children and adults. Research describes observed response rates and monitoring of the agent's presence in the affected tissues. Data for certain groups remain insufficient, and the information is derived from small, mixed patient groups.

Cefadol was evaluated in comparative trials for treating septicemia, which is a severe bloodstream infection. These studies monitored mortality and the clearance of bacteria from the blood. Findings were mixed regarding the success of fully clearing the bacteria, and the research focused on the short-term symptom changes during the acute crisis.


Long-Term Research and Follow-up Durations

The available research primarily focuses on the short-term symptom changes and immediate outcomes related to acute treatment, meaning that long-term effects are not fully established. Most studies observed responses over defined time intervals that covered only the time of drug administration and the immediate period following. There is limited information for long-term outcomes across all studied conditions, including how often infections might return (recurrence) or the sustained stability of the patient's condition many months after the treatment course is completed. Therefore, the evidence largely contributes to understanding acute symptom patterns, but not long-term health evolution.


Research in Specific Patient Groups (Special Populations)

Research has included studies examining Cefadol in certain specific patient populations, including both adults and children with serious infections like septicemia and bone/joint infections. In these mixed-age cohorts, studies monitored outcomes related to systemic or functional imbalance. However, data for certain groups remain insufficient. For instance, while some pediatric patients were included, the overall evidence base varies across studies, and dedicated studies focusing exclusively on special populations like older adults or those with multiple complex comorbid conditions are not consistently available. Subgroup findings are uncertain when trying to extrapolate beyond the general populations studied.


Evidence Gaps and Areas of Scientific Uncertainty

Research so far indicates several important areas where further study is needed. A main limitation is that the follow-up durations were limited across many indications, leaving long-term effects not fully established. The sample sizes were modest in the studies covering conditions like skin/soft tissue and bone/joint infections. In many cases, comparative evidence is lacking against the most commonly used antibiotics today. This means that while studies describe patterns observed in the treatment setting, they do not provide current comparisons against all relevant therapeutic alternatives. In summary, the evidence highlights what is known — and what is still uncertain, underscoring that results apply only to the populations studied and research provides context but not individual predictions.

Key Studies & References

  1. SHC Surgical Antimicrobial Prophylaxis Guideline (Reference for current prophylaxis standards)

Frequently Asked Questions (FAQ)

Common questions about Cefadol (FAQ)

Q: How quickly do people generally notice the effects of Cefadol?

Clinical studies generally monitor short-term symptom changes and bacterial eradication over the course of treatment. Official guidelines recommend continuing the medication for a minimum of 48 to 72 hours after the patient becomes free of symptoms and bacterial clearance is confirmed. A specific timeframe for when a patient may first notice clinical improvement is not detailed in the official product information.

Q: What is the expected length of time Cefadol stays active in the body?

Cefadol is processed and eliminated by the kidneys. For patients with impaired renal function (poor kidney function), regulatory documents require the dosage to be adjusted. The dose adjustment is necessary because kidney impairment can slow the body's clearance of the drug, leading to a prolonged concentration in the body.

Q: Is Cefadol sold over the counter in some countries?

Cefadol is categorized as a prescription-only medication in official regulatory documentation. The drug's formulation as a sterile powder for injection is consistent with its status as a medication intended for administration by a healthcare professional.

Q: Is Cefadol different from (a similar, hypothetical drug name)?

Official classifications define Cefadol's active ingredient as a second-generation cephalosporin antibiotic. Differences from other medications are based on their individual regulatory classifications and specific mechanisms.

Q: Do food or specific types of drinks impact how Cefadol works?

Official guidelines state that Cefadol can generally be taken with or without food. However, there is a mandatory warning requiring the avoidance of all alcohol during treatment and for a period afterward due to the risk of a severe reaction.

Q: Is it common to experience stomach upset when first starting Cefadol?

The safety profile documents adverse reactions categorized under Gastrointestinal Disorders. Official information also explicitly lists pseudomembranous colitis, which is a severe form of inflammation in the colon, as a serious possible reaction.

Q: What are the most commonly reported less serious side effects of Cefadol?

Commonly documented adverse reactions include allergic skin reactions like maculopapular rash and urticaria (hives). Changes in blood tests, such as increased eosinophilia (a type of white blood cell), have also been documented.

Q: Are skin rashes a possible side effect of Cefadol?

Yes, official safety documents list reactions under Skin and Subcutaneous Tissue Disorders. Specifically documented hypersensitivity reactions include a maculopapular rash and urticaria (hives).

Q: Can Cefadol affect liver function test results?

Official safety data indicates that it is possible to experience changes, described as liver enzyme abnormalities. For patients receiving prolonged therapy, monitoring of blood parameters may be considered.

Q: Are there specific warnings about Cefadol use in older adults?

The official research overview notes that while some studies included older individuals, dedicated clinical trials focusing exclusively on the older adult population are not consistently available in the current evidence base.

Q: Is it true that Cefadol is not recommended during pregnancy?

The drug is assigned to FDA Pregnancy Category B. This means that animal studies failed to show a risk to the fetus, but there are no adequate, controlled human studies. Use is therefore limited to when the clinical need has been clearly established.

Q: Is Cefadol known to pass into breast milk?

Yes, regulatory labeling confirms that the active ingredient in Cefadol is known to be excreted into human milk in small amounts.

Q: Have researchers looked into Cefadol's long-term safety?

The official research overview states that follow-up durations in the available studies were limited. Therefore, long-term effects are not fully established, and the evidence primarily contributes to understanding acute symptom patterns during the treatment phase.

Q: What does the published research say about Cefadol's overall effectiveness?

Research describes patterns of clinical response and bacterial clearance in the populations studied for conditions like lower respiratory tract and skin infections. However, the regulatory research overview notes that comparative evidence is lacking against the antibiotics currently considered standard therapeutic agents.

Q: Are there ongoing clinical trials for Cefadol or new uses being studied?

The official research review states that direct, modern comparative evidence is lacking against the most current standard agents used today. The existing evidence is largely focused on historical and foundational data regarding the drug’s original approved uses.

Q: Does Cefadol interact with common cold or flu medications?

The drug's interaction profile lists specific pharmaceutical categories, such as Oral Anticoagulants and Renal Tubular Secretion Inhibitors. Official guidance notes that providing a complete list of all medications, including any common cold or flu treatments, is required for a comprehensive assessment by a healthcare professional.

Q: Can Cefadol be used by individuals who have certain allergies?

Cefadol is contraindicated (absolutely forbidden) for individuals with known allergies to the cephalosporin class of antibiotics. Caution is advised for those with a history of penicillin allergy due to a documented risk of cross-hypersensitivity reactions.

Q: What is the purpose of the different strengths Cefadol is available in?

Regulatory guidelines define a standard dose range for the active ingredient. This range exists to accommodate dosage adjustments that are made based on factors such as the patient’s age, the severity of their symptoms, and their overall health status.

Q: Do you need to stop taking Cefadol gradually, or can you stop immediately?

Regulatory documents state that stopping or adjusting the dosage of this medication requires the direction of a healthcare professional. Guidelines specify that treatment should continue for a minimum of 48 to 72 hours after symptoms are resolved and for a minimum of 10 days for certain specific infections.

Q: What are the restrictions on Cefadol use for people with heart conditions?

While heart conditions are not explicitly listed as a contraindication, official labeling notes that symptoms including hypotension (low blood pressure) may occur following the consumption of alcohol during use.

Q: What happens if a person misses a dose of Cefadol (general advice, not instruction)?

The primary goal of the antibiotic treatment is to achieve bacterial eradication, which is generally confirmed after a minimum of 48 to 72 hours of consistent dosing once symptoms begin to improve. Missing doses may compromise maintaining the necessary drug concentration required to achieve complete bacterial eradication.

Q: Why is Cefadol sometimes mentioned alongside certain blood tests?

Regulatory documents specify that patients with renal impairment require monitoring of their kidney function. Additionally, changes in blood cell counts such as neutropenia (low white blood cells) and thrombocytopenia (low platelet count) have been documented as possible adverse reactions.

Q: Is it common for people to switch from a different drug to Cefadol?

Research indicates that direct, modern comparative evidence is lacking against the most current standard therapeutic agents. This suggests that clinical decisions to switch or initiate treatment are not uniformly supported by recent head-to-head trial data.

Q: What is the general consensus on Cefadol use in children?

The regulatory profile confirms that the drug's usefulness is established in children, with dosing based on body weight. However, the safety profile has not been established in infants under one month of age.

Q: Do regulatory agencies classify Cefadol as a high-risk medication?

The official safety profile explicitly lists Anaphylaxis (a severe allergic reaction) and pseudomembranous colitis as serious adverse reactions. These factors contribute to the overall regulatory risk assessment of the agent.

Q: Are there lifestyle factors that may affect Cefadol's performance?

The regulatory profile includes a timing-based rule for substance avoidance: the mandatory avoidance of all alcohol during treatment and for at least 72 hours after the last dose due to the risk of a severe disulfiram-like reaction.

Q: Is it possible to develop tolerance to Cefadol over time?

Cefadol is an antibiotic, and official scientific documents acknowledge that bacterial resistance to the cephalosporin class is commonly seen when bacteria develop specific beta-lactamase enzymes. This can compromise the drug's effectiveness against the bacteria.

Q: Does Cefadol need to be taken at a specific time of day?

The standard regimen is typically a dosage taken three times daily. Manufacturer's guidelines suggest taking it according to your physician’s instructions, and it can generally be taken with or without food.

Q: Can Cefadol be taken with medications for chronic conditions?

The interaction profile lists specific drug categories, such as Oral Anticoagulants (which are often chronic medications). Regulatory documents require careful monitoring when Cefadol is used concurrently with these agents due to the documented risk of bleeding.

Q: What research is available on Cefadol use in diverse populations?

The official research overview confirms that studies included mixed patient groups (including children and adults) for certain severe infections. However, the evidence states that data for certain subgroups remain insufficient.

Q: Why is Cefadol sometimes given for different conditions?

Official regulatory classifications define the active ingredient as a second-generation cephalosporin with broad-spectrum capability. This classification supports its use across various systemic bacterial infections, including those affecting the respiratory tract, skin, and bones.

How should Cefadol be stored and disposed of?

The storage and disposal requirements for Cefadol (Cefamandole nafate, sterile powder for injection) depend on its state. The unreconstituted powder must be stored at Controlled Room Temperature (20 C to 25 C) in its original carton to protect it from light and moisture. The reconstituted solution requires refrigeration at 5 C and is stable for 96 hours (4 days); it must not be frozen. The product, in all forms, must be stored out of the sight and reach of children. Unused or expired medication must not be disposed of via wastewater; instead, it must be discarded following local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefadol found in:

A-Z Index: